Comparing 3 Schedules of Alimta Plus Gemzar
Sponsor
Eli Lilly and Company (Industry)
Overall Status
Completed
CT.gov ID
NCT00034606
Collaborator
(none)
1
Study Details
Study Description
Brief Summary
The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Diagnosis of non-small lung cancer
-
No prior chemotherapy
-
Able to care for self
Exclusion Criteria:
-
An ongoing infection
-
Pregnancy or breast feeding
-
Other serious medical condition
-
Cancer that has spread to the brain
-
Inability to take folic acid
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rochester | Minnesota | United States |
Sponsors and Collaborators
- Eli Lilly and Company
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00034606
Other Study ID Numbers:
- 5115
- H3E-MC-JMEL
First Posted:
May 2, 2002
Last Update Posted:
Jul 19, 2006
Last Verified:
Jul 1, 2006
Keywords provided by ,
,
Additional relevant MeSH terms: